The ARHGAP23 Knockout A-549 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma epithelial cell line, featuring targeted disruption of the ARHGAP23 gene. This loss-of-function model enables researchers to investigate the consequences of ablating ARHGAP23 expression in a well-characterized cancerous epithelial background. The polyclonal nature of this knockout pool preserves the heterogeneity of editing events, making it suitable for studying population-level effects of ARHGAP23 deficiency without clonal selection bias.
The A-549 host cell line was originally established from the lung adenocarcinoma of a 58-year-old Caucasian male and exhibits an adherent epithelial morphology. As a widely utilized model for alveolar type II epithelial cells, A-549 cells are central to respiratory research, cancer biology, and drug discovery studies. Their robust growth characteristics and relevance to human lung adenocarcinoma make them an ideal platform for examining genes involved in tumor cell motility and cytoskeletal regulation.
ARHGAP23 encodes a Rho GTPase-activating protein (RhoGAP) that accelerates GTP hydrolysis on Rho family members including RhoA, Rac1, and Cdc42, thereby switching them from an active to an inactive state. Its activity is modulated by upstream signals such as integrin-mediated adhesion and growth factor stimulation by EGF and PDGF. Inactivation of Rho GTPases by ARHGAP23 subsequently attenuates downstream effectors including ROCK, PAK, and WASP/WAVE signaling cascades, which control actin dynamics. Representative pathway components influenced by ARHGAP23 include ROCK, PAK, LIMK, cofilin, myosin light chain (MLC), FAK, and paxillin. Consequently, ARHGAP23 functions as a critical brake on cytoskeletal reorganization, cell adhesion, and migration. Disruption of this gene is predicted to increase the levels of active GTP-bound RhoA, Rac1, and Cdc42, leading to enhanced actomyosin contractility, lamellipodia formation, and focal adhesion turnover.
In the context of A-549 lung adenocarcinoma cells, loss of ARHGAP23 presents a powerful model to dissect how elevated Rho GTPase signaling influences epithelial-derived cancer cell behavior. Because A-549 cells retain many characteristics of lung epithelia yet are derived from a malignant tumor, they offer a physiologically relevant system to examine the transition from controlled to dysregulated cell migration and invasion. The knockout population enables experimental interrogation of ARHGAP23??s role in processes thought to drive metastasis, including dynamic actin remodeling, adhesion complex maturation, and directional motility.
This knockout cell product is suited for a wide range of experimental applications. It can be employed in GTPase activation pull-down assays to confirm elevated RhoA, Rac1, or Cdc42 activity, in wound healing and transwell invasion assays to quantify migratory and invasive capacity, and in immunofluorescence studies to visualize changes in F-actin organization and focal adhesion architecture. Western blotting for phospho-MLC and phospho-cofilin provides additional readouts of downstream signaling. Researchers investigating RhoGAP specificity, mechanisms of cancer cell drug resistance, or screening for modulators of cytoskeletal dynamics will find this model valuable. For further information, please contact Ascent Research.
